Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
Chronic respiratory diseases are the third leading cause of death, behind cardiovascular diseases and cancer, affecting approximately 550 million of people all over the world. Most of the chronic respiratory diseases are attributable to asthma and chronic obstructive pulmonary disease (COPD) with th...
Saved in:
Main Authors: | Fabrizio Facchinetti (Author), Maurizio Civelli (Author), Dave Singh (Author), Alberto Papi (Author), Aida Emirova (Author), Mirco Govoni (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder
by: Cataldo Martucci, et al.
Published: (2024) -
Corrigendum: CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder
by: Cataldo Martucci, et al.
Published: (2024) -
Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
by: Jonathan E. Phillips
Published: (2020) -
Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis
by: Xudan Yang, et al.
Published: (2023) -
Intervention on inhalation technique of rotahaler in patients with chronic obstructive pulmonary disease and asthma
by: G.M. Khan, et al.
Published: (2016)